HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Prolonged treatment of HER2 positive breast cancer cells with tyrosine kinase inhibitors (TKIs) leads to the emergence of acquired resistance. However, the effects of continuous TKI exposure on cell fate, and the steps leading to the acquisition of a resistant phenotype are poorly understood. To exp...

Full description

Bibliographic Details
Main Authors: Martina S. J. McDermott, Neil Conlon, Brigid C. Browne, Adam Szabo, Naoise C. Synnott, Neil A. O’Brien, Michael J. Duffy, John Crown, Norma O’Donovan
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
lapatinib
HER2
breast cancer
TKI
erbB2
senescence
neratinib
afatinib
trastuzumab
Online Access:https://www.mdpi.com/2072-6694/11/2/197

Similar Items

Similar Items